Hepatocyte transplantation using a living donor reduced graft in a baby with ornithine transcarbamylase deficiency: A novel source of hepatocytes

Shin Enosawa, Reiko Horikawa, Akiko Yamamoto, Seisuke Sakamoto, Takanobu Shigeta, Shunsuke Nosaka, Junichiro Fujimoto, Akito Tanoue, Kazuaki Nakamura, Akihiro Umezawa, Yoichi Matsubara, Akira Matsui, Mureo Kasahara – 23 November 2013

Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)‐related cirrhosis aware of their HCV status improves survival: A modeling approach

Abbas Mourad, Sylvie Deuffic‐Burban, Nathalie Ganne‐Carrié, Thibaud Renaut‐Vantroys, Isabelle Rosa, Anne‐Marie Bouvier, Guy Launoy, Stephane Cattan, Alexandre Louvet, Sébastien Dharancy, Jean‐Claude Trinchet, Yazdan Yazdanpanah, Philippe Mathurin – 21 November 2013 – Because of the ongoing debate on the benefit of ultrasound (US) screening for hepatocellular carcinoma (HCC), we assessed the impact of screening on hepatitis C virus (HCV)‐related compensated cirrhosis patients aware of their HCV status.

MicroRNA‐26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor‐cMet pathway

Xin Yang, Xiao‐Fei Zhang, Xu Lu, Hu‐Liang Jia, Lei Liang, Qiong‐Zhu Dong, Qing‐Hai Ye, Lun‐Xiu Qin – 21 November 2013 – MicroRNA (miR)‐26a can suppress tumor growth and metastasis of hepatocellular carcinoma (HCC). Since angiogenesis is important for tumor growth and metastasis, we investigated the possible roles of miR‐26a in tumor angiogenesis. Down‐regulation of miR‐26a was found to correlate with an increased angiogenic potential of HCC.

Left‐liver hypertrophy after therapeutic right‐liver radioembolization is substantial but less than after portal vein embolization

Benjamin Garlipp, Thierry Baere, Robert Damm, Romy Irmscher, Mark Buskirk, Patrick Stübs, Frederic Deschamps, Frank Meyer, Ricarda Seidensticker, Konrad Mohnike, Maciej Pech, Holger Amthauer, Hans Lippert, Jens Ricke, Max Seidensticker – 21 November 2013 – In patients with liver malignancies potentially amenable to curative extended right hepatectomy but insufficient size of the future liver remnant (FLR), portal vein embolization (PVE) of the tumor‐bearing liver is used to induce contralateral liver hypertrophy but leaves the tumor untreated.

Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis

Priya Handa, Bryan D. Maliken, James E. Nelson, Vicki Morgan‐Stevenson, Donald J. Messner, Barjinderjit K. Dhillon, Heather M. Klintworth, Mary Beauchamp, Matthew M. Yeh, Clinton T. Elfers, Christian L. Roth, Kris V. Kowdley – 21 November 2013 – Obesity and adiponectin depletion have been associated with the occurrence of nonalcoholic fatty liver disease (NAFLD). The goal of this study was to identify the relationship between weight gain, adiponectin signaling, and development of nonalcoholic steatohepatitis (NASH) in an obese, diabetic mouse model.

Liver‐primed CD8+ T cells suppress antiviral adaptive immunity through galectin‐9‐independent T‐Cell immunoglobulin and mucin 3 engagement of high‐mobility group box 1 in mice

Joseph S. Dolina, Thomas J. Braciale, Young S. Hahn – 20 November 2013 – The liver is a tolerogenic environment exploited by persistent infections, such as hepatitis B (HBV) and C (HCV) viruses. In a murine model of intravenous hepatotropic adenovirus infection, liver‐primed antiviral CD8+ T cells fail to produce proinflammatory cytokines and do not display cytolytic activity characteristic of effector CD8+ T cells generated by infection at an extrahepatic, that is, subcutaneous, site.

Subscribe to